INTELLIGENT VERTICAL: HEALTHCARE
a-Service (SaaS) platform to provide
actionable reports to enable HUS to offer
the best therapeutic options for its patients
based on their genomic profile.
HUS has been a leader in adopting Precision
Medicine and recently accelerated its
capabilities with an investment in Illumina’s
next-generation sequencing (NGS)
infrastructure in 2017. The ability to match
therapeutic recommendations based on a
patient’s genomic profile will result in HUS
being the first hospital in Northern Europe to
deploy these capabilities on a wide scale.
“
CONTINUOUS
MONITORING
SOLUTIONS ARE
COMING CLOSER
TO BECOMING A
STANDARD OF
CARE ACROSS
THE HEALTH
CONTINUUM.
monitoring system is a powerful tool that will
help us mitigate this risk and we are excited
to add it to our ward as part of our total
safety initiative.”
Used worldwide in hospitals, rehab and
skilled nursing facilities, the EarlySense
continuous monitoring system leverages
advanced algorithms to notify nurses of
potentially adverse changes in patient vital
signs, sending alerts to their pagers and to
the central display station. The FDA-cleared
and CE-approved solution has been clinically
96
INTELLIGENTCIO
proven to help prevent adverse events,
including code blues which are a result of
cardiac or respiratory arrest, preventable ICU
transfers, patient falls, pressure ulcers and
hospital readmissions.
“Franciscus Gasthuis and Vlietland is the
latest hospital to join our growing list of
global customers and we are proud to be
included in its vision for patient safety,” said
Yfat Scilaom, VP of International Sales and
Marketing at EarlySense.
“Continuous monitoring solutions are
coming closer to becoming a standard of
care across the health continuum and we are
proud to see EarlySense technology continue
to help patients and healthcare teams across
the world.”
Patient monitoring also includes being able
to monitor data and doing so correctly and
efficiently will allow the healthcare industry
to excel. BC Platforms, a world leader in
genomic data management and analytics,
has announced it is launching its world-
leading genomics platform for HUS, the
Hospital District of Helsinki and Uusimaa
and the largest healthcare service provider in
the whole Nordics region.
BC Platforms will be providing its
customisable end-to-end Software-as-
Advances in technology and the decreasing
costs of NGS has facilitated the rapid
implementation of genomic sequencing
in diagnostics, clinical research and
development. The rapid pace of adoption
has also created challenges for all
stakeholders in clinical genomic sequencing,
including the assistance of outside third-
party vendors to handle the large data
workloads, resulting in calls for standardising
variant interpretation approaches in clinical
molecular laboratories, to ensuring that non-
genetically trained clinicians are prepared to
interpret new types of clinical information
for their patients. Clinical genomics is
rapidly evolving as this new data enables
advances in clinical innovation and complex
implementation questions are resolved.
Mikko Rotonen, Development Director at
HUS, commented: “The ability to incorporate
genomics into our research and clinical
workflows to deliver more effective, precise
and economical care for our patients
seemed to be a daunting task to undertake.
With the possibility of multiple partners
and large amounts of data to be processed
and analysed, we need to have confidence
in a partner to deliver a customised end-
to-end solution that is flexible enough
to incorporate existing and new pipeline
technologies, with quality assurance and
data security measures in place, on a
scalable, easy to use, manageable platform.”
Tero Silvola, CEO of BC Platforms, said:
“HUS is at the forefront of offering the best
quality care and services for its patients.
Incorporating our customisable end-to-end
Software-as-a-Service platform will enable
HUS physicians and staff to become more
efficient and confident in offering the best
therapeutic options for its patients.” n
www.intelligentcio.com